New Delhi, Mar 16 (UNI) Suven Life Sciences Ltd said it has signed an agreement with US based Eli Lilly to receive research funding as well as potential discovery and development milestone payments in the range of 19-23 million dollars per candidate.
The company will also receive potential royalties on net sales of any products that may be successfully commercialised.
The agreement is to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders (CNS).
As per the agreement, Suven will be responsible for discovery activities related to the identification and selection of clinical candidates in the area of CNS, in close association with Lilly.
UNI BJR SG KN1422